Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, \>/=18 years of age
Locally advanced or metastatic (stage III/IV) non-small cell lung cancer with EGFR mutations
Measurable disease according to RECIST criteria
ECOG performance status 0-2
Adequate haematological, renal and liver function
You may not be if
Previous chemotherapy or therapy against EGFR for metastatic disease
History of another malignancy, except for in situ carcinoma of the cervix, adequately treated basal cell skin carcinoma, or radically treated prostate carcinoma with good prognosis
Symptomatic cerebral metastases
Pre-existing parenchymal lung disease such as pulmonary fibrosis
Concomitant use of coumarins
Clareo Health | A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations
